Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Lixin Guo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, …. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glycemic Control, Insulin, Long-Acting. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
To investigate glycaemic control in Chinese adults with type 2 diabetes (T2D) initiating, or switching to insulin degludec/insulin aspart (IDegAsp), a co‐formulation of basal, and bolus insulin, in a real‐world setting. Materials and Methods A 20‐week, prospective, single‐arm, open‐label, non‐interventional study was conducted in Chinese adults with T2D initiating, or switching to IDegAsp after anti‐hyperglycaemic treatment with oral antidiabetic drugs (OADs), other insulins, or glucagon‐like peptide‐1 receptor agonists. The primary endpoint was a change in HbA 1c from baseline to end of the study; the secondary endpoints included a change in fasting plasma glucose and Diabetes Treatment Satisfaction Questionnaire (DTSQ) score.
Results
Significant reductions were observed in mean HbA 1c and fasting plasma glucose, among both the overall population ( N = 878; −1.27%‐points [95% CI: −1.36; −1.19]; p < 0.0001, and −1.61 mmol/L [95% CI: −1.81; −1.41]; p < 0.0001, respectively), and in subgroups switching from OADs only, or basal, or premix insulins ± OADs. The mean total DTSQ score increased from 26.4 (baseline) to 31.6 (end‐of‐study). No significant, or unexpected tolerability, or safety issues were observed. Significant reductions were observed in incidence rates of non‐severe (rate ratio 0.37 [95% CI: 0.24; 0.59]; p < 0.0001) and nocturnal non‐severe (rate ratio 0.45 [95% CI: 0.21; 0.94]; p = 0.0326) hypoglycaemic episodes.
Conclusions
In a broad, real‐world Chinese population of adults with T2D, initiating or switching to IDegAsp was associated with improved glycaemic control and lower rates of hypoglycaemia. The use of IDegAsp could be an effective treatment option for those with suboptimal glycaemic control or therapeutic inertia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
- Chu Hsien-I Memorial Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
- The People's Hospital of Jiangmen, Jiangmen, China.
- The Second Hospital of Chifeng, Chifeng, China.
- Hubei University of Medicine, Shiyan, China.
- Endocrinology Department, Jiangning Hospital affiliated to Nanjing Medical University, Nanjing, China.
ORCID-Profile: Lixin Guo, Liming Chen
Förderung
- Novo Nordisk
Zitieren
APA
Guo, L., Chen, L., Zhao, F., Liu, X., Ding, H., Wang, K., Zhong, X., Shankarappa, V. B., & Chaudhary, G. (2025). Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16139
Vancouver
Guo L, Chen L, Zhao F, Liu X, Ding H, Wang K, et al. Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16139
BibTeX
@article{Guo2025,
author = {Guo, Lixin and Chen, Liming and Zhao, Fan and Liu, Xiaoyun and Ding, Hongcheng and Wang, Kun and Zhong, Xing and Shankarappa, Vinay Babu and Chaudhary, Gaurav},
title = {Improved glycaemic control in people with type 2 diabetes initiating or switching to IDegAsp in a real‐world setting in China},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16139}
}
EUVIMED